Lenvatinib reported that FGF19 levels and lenvatinib susceptibility were correlated in HCC cell lines, and FGF19 inhibition eliminated lenvatinib susceptibility [23]. This evidence concerns the gene FGF19 and hepatocellular carcinoma.